AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (462.7 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

The advanced development of molecular targeted therapy for hepatocellular carcinoma

Tao Yan1,2,*, Lingxiang Yu3,*, Ning Zhang1, Caiyun Peng1, Guodong Su1, Yi Jing1, Linzhi Zhang1, Tong Wu1, Jiamin Cheng1, Qian Guo2, Xiaoliang Shi4 ( ), Yinying Lu1,2,5 ( )
Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
The Second Department of Hepatobiliary Surgery, Senior Department of Hepatology, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
Shanghai OrigiMed Co., Ltd., Shanghai 201112, China
National Clinical Medical Research Center for Infectious Diseases, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China

*These authors contributed equally to this work.

Show Author Information

Abstract

Hepatocellular carcinoma (HCC), one of the most common malignant tumors in China, severely threatens the life and health of patients. In recent years, precision medicine, clinical diagnoses, treatments, and innovative research have led to important breakthroughs in HCC care. The discovery of new biomarkers and the promotion of liquid biopsy technologies have greatly facilitated the early diagnosis and treatment of HCC. Progress in targeted therapy and immunotherapy has provided more choices for precise HCC treatment. Multiomics technologies, such as genomics, transcriptomics, and metabolomics, have enabled deeper understanding of the occurrence and development mechanisms, heterogeneity, and genetic mutation characteristics of HCC. The continued promotion and accurate typing of HCC, accurate guidance of treatment, and accurate prognostication have provided more treatment opportunities and prolonged survival timelines for patients with HCC. Innovative HCC research providing an in-depth understanding of the biological characteristics of HCC will be translated into accurate clinical practices for the diagnosis and treatment of HCC.

Keywords

immunotherapytargeted therapyHepatocellular carcinomaprecision medicineliquid biopsy

References

1

Wang C, Cao Y, Yang C, Bernards R, Qin W. Exploring liver cancer biology through functional genetic screens. Nat Rev Gastroenterol Hepatol. 2021; 18: 690-704.
Crossref Google Scholar
2

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424.
Crossref Google Scholar
3

Lindblad KE, Ruiz de Galarreta M, Lujambio A. Tumor-intrinsic mechanisms regulating immune exclusion in liver cancers. Front Immunol. 2021; 12: 642958.
Crossref Google Scholar
4

Meng Z, Ren Q, Zhong G, Li S, Chen Y, Wu W, et al. Non-invasive detection of hepatocellular carcinoma with circulating tumor DNA features and alpha-fetoprotein. J Mol Diagn. 2021; 23: 1174-84.
Crossref Google Scholar
5

Ringelhan M, Pfister D, O’Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018; 19: 222-32.
Crossref Google Scholar
6

Cheu JW, Wong CC. Mechanistic rationales guiding combination hepatocellular carcinoma therapies involving immune checkpoint inhibitors. Hepatology (Baltimore, MD). 2021; 74: 2264-76.
Crossref Google Scholar
7

Caines A, Selim R, Salgia R. The changing global epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2020; 24: 535-47.
Crossref Google Scholar
8

Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016; 64(Suppl 1): S84-101.
Crossref Google Scholar
9

Cai H, Jing C, Chang X, Ding D, Han T, Yang J, et al. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing. J Transl Med. 2019; 17: 189.
Crossref Google Scholar
10

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: E359-86.
Crossref Google Scholar
11

Mu X-M, Wang W, Jiang Y-Y, Feng J. Patterns of comorbidity in hepatocellular carcinoma: a network perspective. Int J Environ Res Public Health. 2020; 17: 3108.
Crossref Google Scholar
12

Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, et al. International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer. 2020; 147: 317-30.
Crossref Google Scholar
13

Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16: 589-604.
Crossref Google Scholar
14

Twilt M. Precision medicine: the new era in medicine. EBioMedicine. 2016; 4: 24-5.
Crossref Google Scholar
15

Vitale A, Peck-Radosavljevic M, Giannini EG, Vibert E, Sieghart W, Van Poucke S, et al. Personalized treatment of patients with very early hepatocellular carcinoma. J Hepatol. 2017; 66: 412-23.
Crossref Google Scholar
16

Martin SP, Wang XW. The evolving landscape of precision medicine in primary liver cancer. Hepat Oncol. 2019; 6: HEP12.
Crossref Google Scholar
17

Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020; 73: 1368-78.
Crossref Google Scholar
18

Liu Z, Wu M, Lin D, Li N. Des-gamma-carboxyprothrombin is a favorable biomarker for the early diagnosis of alfa-fetoprotein-negative hepatitis B virus-related hepatocellular carcinoma. J Int Med Res. 2020; 48: 300060520902575.
Crossref Google Scholar
19

Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004; 130: 417-22.
Crossref Google Scholar
20

Zhou J, Sun HC, Wang Z, Cong WM, Wang JH, Zeng MS, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer. 2018; 7: 235-60.
Crossref Google Scholar
21

Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018; 154: 1706-18.e1.
Crossref Google Scholar
22

Gai W, Sun K. Epigenetic biomarkers in cell-free DNA and applications in liquid biopsy. Genes (Basel). 2019; 10: 32.
Crossref Google Scholar
23

Tapper EB, Lok AS. Use of liver imaging and biopsy in clinical practice. N Eng J Med. 2017; 377: 756-68.
Crossref Google Scholar
24

Lin DC, Mayakonda A, Dinh HQ, Huang P, Lin L, Liu X, et al. Genomic and epigenomic heterogeneity of hepatocellular carcinoma. Cancer Res. 2017; 77: 2255-65.
Crossref Google Scholar
25

Xue R, Li R, Guo H, Guo L, Su Z, Ni X, et al. Variable intra-tumor genomic heterogeneity of multiple lesions in patients with hepatocellular carcinoma. Gastroenterology. 2016; 150: 998-1008.
Crossref Google Scholar
26

Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017; 152: 745-61.
Crossref Google Scholar
27

De Sousa Linhares A, Battin C, Jutz S, Leitner J, Hafner C, Tobias J, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. Sci Rep. 2019; 9: 11472.
Crossref Google Scholar
28

Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology (Baltimore, MD). 2004; 40: 667-76.
Crossref Google Scholar
29

Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (Baltimore, MD). 2007; 45: 42-52.
Crossref Google Scholar
30

Hoshida Y, Nijman SMB, Kobayashi M, Chan JA, Brunet JP, Chiang DY, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 2009; 69: 7385-92.
Crossref Google Scholar
31

Yang C, Huang X, Liu Z, Qin W, Wang C. Metabolism-associated molecular classification of hepatocellular carcinoma. Mol Oncol. 2020; 14: 896-913.
Crossref Google Scholar
32

Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015; 47: 505-11.
Crossref Google Scholar
33

Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, Shiraishi Y, et al. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet. 2016; 48: 500-09.
Crossref Google Scholar
34

Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell. 2019; 179: 561-77.e22.
Crossref Google Scholar
35

Jiang Y, Sun A, Zhao Y, Ying W, Sun H, Yang X, et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature. 2019; 567: 257-61.
Crossref Google Scholar
36

Sia D, Llovet JM. Liver cancer: Translating’ -omics’ results into precision medicine for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2017; 14: 571-72.
Crossref Google Scholar
37

Yang C, Chen J, Li Y, Huang X, Liu Z, Wang J, et al. Exploring subclass-specific therapeutic agents for hepatocellular carcinoma by informatics-guided drug screen. Brief Bioinform. 2021; 22: bbaa295.
Crossref Google Scholar
38

Nishioka ST, Sato MM, Wong LL, Tiirikainen M, Kwee SA. Clinical and molecular sub-classification of hepatocellular carcinoma relative to alpha-fetoprotein level in an Asia-Pacific island cohort. Hepatoma Res. 2018; 4: 1.
Crossref Google Scholar
39

Schmidt B, Wei L, DePeralta DK, Hoshida Y, Tan PS, Sun X, et al. Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition. Int J Cancer. 2016; 138: 1494-505.
Crossref Google Scholar
40

Kim MY, Oskarsson T, Acharyya S, Nguyen DX, Zhang HF, Norton L, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009; 139: 1315-26.
Crossref Google Scholar
41

Guo W, Sun YF, Shen MN, Ma XL, Wu J, Zhang CY, et al. Circulating tumor cells with stem-like phenotypes for diagnosis, prognosis, and therapeutic response evaluation in hepatocellular carcinoma. Clin Cancer Res. 2018; 24: 2203-13.
Crossref Google Scholar
42

Wang PX, Xu Y, Sun YF, Cheng JW, Zhou KQ, Wu SY, et al. Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. Liver Int. 2021; 41: 562-73.
Crossref Google Scholar
43

Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019; 13: 125-37.
Crossref Google Scholar
44

Fonseca AL, Cha CH. Hepatocellular carcinoma: a comprehensive overview of surgical therapy. J Surg Oncol. 2014; 110: 712-9.
Crossref Google Scholar
45

Nishikawa H, Kimura T, Kita R, Osaki Y. Radiofrequency ablation for hepatocellular carcinoma. Int J Hyperthermia. 2013; 29: 558-68.
Crossref Google Scholar
46

Singhal A, Jayaraman M, Dhanasekaran DN, Kohli V. Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Crit Rev Oncol Hematol. 2012; 82: 116-40.
Crossref Google Scholar
47

Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69: 89-95.
Crossref Google Scholar
48

European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; 69: 182-236.
Crossref Google Scholar
49

Llovet JM, Peña CEA, Lathia CD, Shan M, Meinhardt G, Bruix J. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012; 18: 2290-300.
Crossref Google Scholar
50

da Fonseca LG, Barroso-Sousa R, Bento Ada SA, Blanco BP, Valente GL, Pfiffer TEF, et al. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Med Oncol (Northwood, London, England). 2014; 31: 264.
Crossref Google Scholar
51

Gardini AC, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini D, et al. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget. 2016; 7: 67142-9.
Crossref Google Scholar
52

Kamachi S, Mizuta T, Otsuka T, Nakashita S, Ide Y, Miyoshi A, et al. Sarcopenia is a risk factor for the recurrence of hepatocellular carcinoma after curative treatment. Hepatol Res. 2016; 46: 201-08.
Crossref Google Scholar
53

Marasco G, Serenari M, Renzulli M, Alemanni LV, Rossini B, Pettinari I, et al. Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments. J Gastroenterol. 2020; 55: 927-43.
Crossref Google Scholar
54

Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase Ⅲ studies. J Hepatol. 2017; 67: 999-1008.
Crossref Google Scholar
55
Adigun OO, Yarrarapu SNS, Khetarpal S. Alpha fetoprotein. In: Statpearls. Treasure Island, FL: StatPearls Publishing; 2021.
56

Liu D, Luo Y, Chen L, Chen L, Zuo D, Li Y, et al. Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: a large-scale, retrospective study. Cancer Biol Med. 2021; 18: 256-70.
Crossref Google Scholar
57

Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment. Cells. 2020; 9: 1370.
Crossref Google Scholar
58

Zhang Y, Wang DC, Shi L, Zhu B, Min Z, Jin J. Genome analyses identify the genetic modification of lung cancer subtypes. Semin Cancer Biol. 2017; 42: 20-30.
Crossref Google Scholar
59

Lee JS. The mutational landscape of hepatocellular carcinoma. Clin Mol Hepatol. 2015; 21: 220-29.
Crossref Google Scholar
60

Attallah AM, Shiha GE, Ismail H, Mansy SE, El-Sherbiny R, El-Dosoky I. Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection. Clin Biochem. 2009; 42: 455-61.
Crossref Google Scholar
61

Lei QQ, Liu JW, Zheng H. Potential role of anti-p53 antibody in diagnosis of lung cancer: evidence from a bivariate meta-analysis. Eur Rev Med Pharmacol Sci. 2013; 17: 3012-18.
Google Scholar
62

De Stefano F, Chacon E, Turcios L, Marti F, Gedaly R. Novel biomarkers in hepatocellular carcinoma. Dig Liver Dis. 2018; 50: 1115-23.
Crossref Google Scholar
63

Qi LN, Bai T, Chen ZS, Wu FX, Chen YY, De Xiang B, et al. The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China: role of chronic hepatitis B virus infection and aflatoxin B1 exposure. Liver Int. 2015; 35: 999-1009.
Crossref Google Scholar
64

Chang Y, Liu B, Niu H, Wang Z, Xia S, Li H. Value of anti-p53 antibody as a biomarker for hepatocellular carcinoma: evidence from a meta-analysis. Medicine (Baltimore). 2020; 99: e21887.
Crossref Google Scholar
65

Kim G, Kurnit KC, Djordjevic B, Singh C, Munsell MF, Wang WL, et al. Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association. Mod Pathol. 2018; 31: 1553-59.
Crossref Google Scholar
66

Kahana-Edwin S, McCowage G, Cain L, Saletta F, Yuksel A, Graf N, et al. Exploration of CTNNB1 ctDNA as a putative biomarker for hepatoblastoma. Pediatr Blood Cancer. 2020; 67: e28594.
Crossref Google Scholar
67

Gao C, Wang Y, Broaddus R, Sun L, Xue F, Zhang W. Exon 3 mutations of CTNNB1 drive tumorigenesis: a review. Oncotarget 2017; 9: 5492-508.
Crossref Google Scholar
68

Harding JJ, Nandakumar S, Armenia J, Khalil DN, Albano M, Ly M, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 2019; 25: 2116-26.
Crossref Google Scholar
69

Nault JC, Calderaro J, Di Tommaso L, Balabaud C, Zafrani ES, Bioulac-Sage P, et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology (Baltimore, MD). 2014; 60: 1983-92.
Crossref Google Scholar
70

Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013; 4: 2218.
Crossref Google Scholar
71

Jiao J, Watt GP, Stevenson HL, Calderone TL, Fisher-Hoch SP, Ye Y, et al. Telomerase reverse transcriptase mutations in plasma DNA in patients with hepatocellular carcinoma or cirrhosis: prevalence and risk factors. Hepatol Commun. 2018; 2: 718-31.
Crossref Google Scholar
72

Chen YL, Jeng YM, Chang CN, Lee HJ, Hsu HC, Lai PL, et al. TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection. Int J Surg (London, UK). 2014; 12: 659-65.
Crossref Google Scholar
73

Shigesawa T, Suda G, Kimura M, Shimazaki T, Maehara O, Yamada R, et al. Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. JGH Open. 2020; 4: 880-88.
Crossref Google Scholar
74

Myojin Y, Kodama T, Maesaka K, Motooka D, Sato Y, Tanaka S, et al. ST6GAL1 is a novel serum biomarker for lenvatinib-susceptible FGF19-driven hepatocellular carcinoma. Clin Cancer Res. 2021; 27: 1150-61.
Crossref Google Scholar
75

Ye X, Wang X, Yu W, Yang Q, Li Y, Jin Y, et al. Synergistic effects of AAGL and anti-PD-1 on hepatocellular carcinoma through lymphocyte recruitment to the liver. Cancer Biol Med. 2021; 18: 1092-108.
Crossref Google Scholar
76

Jung HI, Jeong D, Ji S, Ahn TS, Bae SH, Chin S, et al. Overexpression of PD-L1 and PF-L2 is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res Treat. 2017; 49: 246-54.
Crossref Google Scholar
77

Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies D, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002; 8: 793-800.
Crossref Google Scholar
78

Sangro B, Melero I, Wadhawan S, Finn RS, Abou-Alfa GK, Cheng AL, et al. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020; 73: 1460-69.
Crossref Google Scholar
79

Zhu A, Finn R, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19: 940-52.
Crossref Google Scholar
80

Feun LG, Li YY, Wu C, Wangpaichitr M, Jones PD, Richman SP, et al. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma. Cancer. 2019; 125: 3603-14.
Crossref Google Scholar
81

Zhou KI, Peterson B, Serritella A, Thomas J, Reizine N, Moya S, et al. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin Cancer Res. 2020; 26: 6453-63.
Crossref Google Scholar
82

Ben Dori S, Aizic A, Sabo E, Hershkovitz D. Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2020; 147: 91-98.
Crossref Google Scholar
83

Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017; 377: 2500-01.
Crossref Google Scholar
84

Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160: 48-61.
Crossref Google Scholar
85

Garcia-Saenz JA, Ayllon P, Laig M, Acosta-Eyzaguirre D, Garcia-Esquinas M, Montes M, et al. Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging. BMC Cancer. 2017; 17: 210.
Crossref Google Scholar
86

Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018; 362(6411): eaar3593.
Crossref Google Scholar
87

Wong CN, Fessas P, Dominy K, Mauri FA, Kaneko T, Parcq PD, et al. Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma. Liver Int. 2021; 41: 192-203.
Crossref Google Scholar
88

Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 2019; 10: 4018-25.
Crossref Google Scholar
89

Xu H, Liang XL, Liu XG, Chen NP. The landscape of PD-L1 expression and somatic mutations in hepatocellular carcinoma. J Gastrointest Oncol. 2021; 12: 1132-40.
Crossref Google Scholar
90

Huo J, Wu L, Zang Y. A prognostic model of 15 immune-related gene pairs associated with tumor mutation burden for hepatocellular carcinoma. Front Mol Biosci. 2020; 7: 581354.
Crossref Google Scholar
91

Wang J, Lou J, Fu L, Jin Q. An independent poor-prognosis subtype of hepatocellular carcinoma based on the tumor microenvironment. J Int Med Res. 2021; 49: 300060520980646.
Crossref Google Scholar
92

Du X, Zhang Y. Integrated analysis of immunity- and ferroptosis-related biomarker signatures to improve the prognosis prediction of hepatocellular carcinoma. Front Genet. 2020; 11: 614888.
Crossref Google Scholar
93

Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: present and future. J Gastroenterol Hepatol. 2012; 27: 862-72.
Crossref Google Scholar
94

Ierardi E, Rosania R, Zotti M, Giorgio F, Prencipe S, Valle ND, et al. From chronic liver disorders to hepatocellular carcinoma: molecular and genetic pathways. World J Gastrointest Oncol. 2010; 2: 259-64.
Crossref Google Scholar
95

Pang RWC, Poon RTP. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology. 2007; 72(Suppl 1): 30-44.
Crossref Google Scholar
96

Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011; 8: 292-301.
Crossref Google Scholar
97

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-90.
Crossref Google Scholar
98

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomized, double-blind, placebocontrolled trial. Lancet Oncol. 2009; 10: 25-34.
Crossref Google Scholar
99

Alsina AE, Makris A, Nenos V, Sucre E, Arrobas J, Franco E, et al. Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study. Am Surg. 2014; 80: 680-84.
Crossref Google Scholar
100

Pfeiffenberger J, Koschny R, Hoffmann K, Mehrabi A, Schmitz A, Radeleff B, et al. Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation. Langenbeck’s Arch Surg. 2013; 398: 1123-28.
Crossref Google Scholar
101

Yoshimoto T, Imura S, Morine Y, Ikemoto T, Arakawa Y, Iwahashi S, et al. The outcome of sorafenib therapy on unresectable hepatocellular carcinoma: experience of conversion and salvage hepatectomy. Anticancer Res. 2018; 38: 501-07.
Crossref Google Scholar
102

Rovesti G, Orsi G, Kalliopi A, Vivaldi C, Marisi G, Faloppi L, et al. Impact of baseline characteristics on the overall survival of HCC patients treated with sorafenib: ten years of experience. Gastrointest Tumors. 2019; 6: 92-107.
Crossref Google Scholar
103

Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017; 2: 565-75.
Crossref Google Scholar
104

Yuan J, Yin X, Tang B, Ma H, Zhang L, Li L, et al. Transarterial chemoembolization (TACE) combined with sorafenib in treatment of HBV background hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study. Biomed Res Int. 2019; 2019: 2141859.
Crossref Google Scholar
105

Ren B, Wang W, Shen J, Li W, Ni C, Zhu X. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE alone for unresectable hepatocellular carcinoma: a propensity score matching study. J Cancer. 2019; 10: 1189-96.
Crossref Google Scholar
106

Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020; 69: 1492-501.
Crossref Google Scholar
107

Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, et al. Phase Ⅲ study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011; 47: 2117-27.
Crossref Google Scholar
108

Yeh CC, Hsu CH, Shao YY, Ho WC, Tsai MH, Feng WC, et al. Integrated stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomic analysis identifies Galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancer. Mol Cell Proteomics. 2015; 14: 1527-45.
Crossref Google Scholar
109

Kim HY, Lee DH, Lee J-H, Cho YY, Cho EJ, Yu SJ, et al. Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study. BMC Cancer. 2018; 18: 307.
Crossref Google Scholar
110

Kim H, Yu SJ, Yeo I, Cho YY, Lee DH, Cho Y, et al. Prediction of response to sorafenib in hepatocellular carcinoma: a putative marker panel by multiple reaction monitoring-mass spectrometry (MRM-MS). Mol Cell Proteomics. 2017; 16: 1312-23.
Crossref Google Scholar
111

Gao J-J, Shi Z-Y, Xia J-F, Inagaki Y, Tang W. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol. 2015; 21: 12059-70.
Crossref Google Scholar
112

Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase Ⅲ trial. J Clin Oncol. 2013; 31: 4067-75.
Crossref Google Scholar
113

Cainap C, Qin S, Huang W-T, Chung IJ, Pan H, Cheng Y, et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase Ⅲ trial. J Clin Oncol. 2015; 33: 172-9.
Crossref Google Scholar
114

Cheng AL, Thongprasert S, Lim HY, Sukeepaisarnjaroen W, Yang TS, Wu CC, et al. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. Hepatology (Baltimore, MD). 2016; 64: 774-84.
Crossref Google Scholar
115

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391: 1163-73.
Crossref Google Scholar
116

Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child–Pugh a liver function: a proof-of-concept study. Cancers. 2019; 11: 1084.
Crossref Google Scholar
117

Koizumi Y, Hirooka M, Hiraoka A, Ochi H, Tanaka T, Yukimoto A, et al. Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma. Endocr J. 2019; 66: 787-92.
Crossref Google Scholar
118

Kobayashi M, Kudo M, Izumi N, Kaneko S, Azuma M, Copher R, et al. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. J Gastroenterol. 2019; 54: 558-70.
Crossref Google Scholar
119

Bi F, Qin S, Gu S, Bai Y, Chen Z, Wang Z, et al. Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: an open-label, randomized, multicenter phase Ⅱ/Ⅲ trial. J Clin Oncol. 2020; 38: 4506.
Crossref Google Scholar
120

Shlomai A, Leshno M, Goldstein DA. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis. PLoS One 2018; 13: e0207132.
Crossref Google Scholar
121

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389: 56-66.
Crossref Google Scholar
122

Teufel M, Seidel H, Köchert K, Meinhardt G, Finn RS, Llovet JM, et al. Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Gastroenterology. 2019; 156: 1731-41.
Crossref Google Scholar
123

Kuzuya T, Ishigami M, Ito T, Ishizu Y, Honda T, Ishikawa T, et al. Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment. Hepatol Res. 2019; 49: 1054-65.
Crossref Google Scholar
124

Gillani SW, Moosvi AF. Clinical review: Safety and efficacy comparison between sulfonylureas and dipeptidyl peptidase-4 inhibitors as second-line therapies in type 2 diabetes mellitus. Curr Pharm Des. 2020; 26: 4315-22.
Crossref Google Scholar
125

Ogasawara S, Chiba T, Ooka Y, Suzuki E, Maeda T, Yokoyama M, et al. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Invest New Drugs. 2018; 36: 332-9.
Crossref Google Scholar
126

Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018; 379: 54-63.
Crossref Google Scholar
127

Li JY, Jing R, Wei H, Wang M, Xiaowei Q, Liu H, et al. Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer. Int J Cancer. 2019; 144: 281-9.
Crossref Google Scholar
128

Sieg M, Hartmann M, Settmacher U, Arefian H. Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States. BMC Gastroenterol. 2020; 20: 120.
Crossref Google Scholar
129
Ramucirumab. In: Livertox: Clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
130

Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015; 16: 859-70.
Crossref Google Scholar
131

De Luca E, Marino D, Di Maio M. Ramucirumab, a second-line option for patients with hepatocellular carcinoma: a review of the evidence. Cancer Manag. Res. 2020; 12: 3721-29.
Crossref Google Scholar
132

Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, et al. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. J Gastroenterol. 2020; 55: 627-39.
Crossref Google Scholar
133

Montal R, Andreu-Oller C, Bassaganyas L, Esteban-Fabró R, Moran S, Montironi C, et al. Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. Br J Cancer. 2019; 121: 340-43.
Crossref Google Scholar
134

He W, Liao L, Hu D, Li B, Wang C, Qiu J, et al. Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study. Ann Transl Med. 2020; 8: 1000.
Crossref Google Scholar
135

Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007; 96: 1788-95.
Crossref Google Scholar
136

Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019; 20: 1070-82.
Crossref Google Scholar
137

Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 2021; 40: 184.
Crossref Google Scholar
138

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-23.
Crossref Google Scholar
139

Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013; 59: 81-8.
Crossref Google Scholar
140

Wang J, Li J, Tang G, Tian Y, Su S, Li Y. Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma. Oncol Lett. 2021; 21: 279.
Crossref Google Scholar
141

El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389: 2492-502.
Crossref Google Scholar
142

Teng W, Lin CC, Ho MM, Lui KW, Wang SF, Hsu CW, et al. Alpha-fetoprotein response at different time-points is associated with efficacy of nivolumab monotherapy for unresectable hepatocellular carcinoma. Am J Cancer Res. 2021; 11: 2319-30.
Google Scholar
143

Oh S, Park Y, Lee HJ, Lee J, Lee SH, Baek YS, et al. A disintegrin and metalloproteinase 9 (ADAM9) in advanced hepatocellular carcinoma and their role as a biomarker during hepatocellular carcinoma immunotherapy. Cancers (Basel). 2020; 12: 745.
Crossref Google Scholar
144

Hung HC, Lee JC, Wang YC, Cheng CH, Wu TH, Lee CF, et al. Response prediction in immune checkpoint inhibitor immunotherapy for advanced hepatocellular carcinoma. Cancers (Basel). 2021; 13: 1607.
Crossref Google Scholar
145

Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. LBA38_PR-Checkmate 459: a randomized, multi-center phase Ⅲ study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2019; 30: 874-5.
Crossref Google Scholar
146

Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020; 38: 2960-70.
Crossref Google Scholar
147

Van Laethem J, Borbath I, Karwal M, Verslype C, Van Vlierberghe H, Kardosh A, et al. Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase Ⅱ KEYNOTE-224 study. J Clin Oncol. 2021; 39: 297-7.
Crossref Google Scholar
148

Chiang CL, Chan SK, Lee SF, Wong IO, Choi HC. Cost-effectiveness of pembrolizumab as a second-line therapy for hepatocellular carcinoma. JAMA Netw Open. 2021; 4: e2033761.
Crossref Google Scholar
149

Kiyotani K, Toyoshima Y, Nakamura Y. Personalized immunotherapy in cancer precision medicine. Cancer Biol Med. 2021; 18: 955-65.
Crossref Google Scholar
150

Colli LM, Machiela MJ, Zhang H, Myers TA, Jessop L, Delattre O, et al. Landscape of combination immunotherapy and targeted therapy to improve cancer management. Cancer Res. 2017; 77: 3666-71.
Crossref Google Scholar
151

Wang Y, Lu L, Guan Y, Ho M, Lu S, Spahn J, et al. Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance. Exp Hematol Oncol. 2021; 10: 45.
Crossref Google Scholar
152

Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020; 21: 808-20.
Crossref Google Scholar
153

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019; 381: 2020-31.
Crossref Google Scholar
154

Pan C, Liu H, Robins E, Song W, Liu D, Li Z, et al. Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy. J Hematol Oncol. 2020; 13: 29.
Crossref Google Scholar
155

Cheng H, Sun G, Chen H, Li Y, Han Z, Li Y, et al. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies. Am J Cancer Res. 2019; 9: 1536-45.
Google Scholar
156

Plaz Torres MC, Lai Q, Piscaglia F, Caturelli E, Cabibbo G, Biasini E, et al. Treatment of hepatocellular carcinoma with immune checkpoint inhibitors and applicability of first-line Atezolizumab/Bevacizumab in a real-life setting. J Clin Med. 2021; 10: 3201.
Crossref Google Scholar
157

Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, et al. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology (Baltimore, MD). 2015; 61: 1591-602.
Crossref Google Scholar
158

Kimura T, Kato Y, Ozawa Y, Kodama K, Ito J, Ichikawa K, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018; 109: 3993-4002.
Crossref Google Scholar
159

Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ t cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019; 14: e0212513.
Crossref Google Scholar
160

Llovet JM, Kudo M, Cheng AL, Finn RS, Zhu AX. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study. J Clin Oncol. 2019; 37: TPS4152.
Crossref Google Scholar
161

Joerger M, Güller U, Bastian S, Driessen C, von Moos R. Prolonged tumor response associated with sequential immune checkpoint inhibitor combination treatment and regorafenib in a patient with advanced pretreated hepatocellular carcinoma. J Gastrointest Oncol. 2019; 10: 373-8.
Crossref Google Scholar
162

Chen X, Zhang Y, Zhang N, Ge Y, Jia W. Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report. Onco Targets Ther. 2019; 12: 7355-59.
Crossref Google Scholar
163

Kudo M, Ikeda M, Motomura K, Okusaka T, Kobayashi M. A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): study 117. J Clin Oncol. 2020; 38: 513.
Crossref Google Scholar
164

Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018; 378: 158-68.
Crossref Google Scholar
165

Cappelli LC, Gutierrez AK, Bingham CO, 3rd, Shah AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res. 2017; 69: 1751-63.
Crossref Google Scholar
166

Zhang J, Shi Z, Xu X, Yu Z, Mi J. The influence of microenvironment on tumor immunotherapy. FEBS J. 2019; 286: 4160-75.
Crossref Google Scholar
167

Fessas P, Possamai LA, Clark J, Daniels E, Gudd C, Mullish BH, et al. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology. 2020; 159: 167-77.
Crossref Google Scholar
Cancer Biology & Medicine
Volume 19 Issue 6,
June 2022
Pages 802-817
DOI: 10.20892/j.issn.2095-3941.2021.0661
Cite this article:
Yan T, Yu L, Zhang N, et al. The advanced development of molecular targeted therapy for hepatocellular carcinoma. Cancer Biology & Medicine, 2022, 19(6): 802-817. https://doi.org/10.20892/j.issn.2095-3941.2021.0661

170

Views

3

Downloads

26

Crossref

22

Web of Science

24

Scopus

Altmetrics
Received: 09 December 2021
Accepted: 18 April 2022
Published: 15 June 2022
©2022 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License
Return